Lenti-EF1a-EGFRvIII- 2nd-CAR-puro

【No.】LIC007A 【Name】 Lenti-EF1a-EGFRvIII- 2nd-CAR-puro
【Plasmid resistance】Amp 【Target】hEGFRvIII
【Activation signal】4-1BB/CD3(Zeta) 【Packing specifications】4μg/tube

EGFR is the expression product of the proto-oncogene C-erbB-1. It is a membrane receptor protein with a relative molecular mass of 170KD. It is widely present on the cell membrane of mammals. EGFR is widely expressed in epidermal cells and stromal cells, and can also be expressed in some smooth muscle cells and glial cells. It plays a very important role in regulating cell growth and tissue repair. EGFR can cause cell growth, proliferation and differentiation after being combined with its ligands. It plays a very important regulatory role in the normal physiological process of human cells, and its overexpression is related to cell carcinogenesis. Studies have found that during the occurrence and development of tumors, the expression of EGFR protein is not very stable, and gene amplification, rearrangement and mutations often occur, causing corresponding changes in the antigen phenotype on the surface of tumor cells. Among them, EGFRvIII is the most common form of epidermal growth factor mutation. Compared with the complete structure, the 2nd~7th exons of EGFR exons are deleted, resulting in the deletion of 801 base pairs. The deletion end is connected by a new codon-glycine, EGFRvIII It can constitutively activate tyrosine kinase without any ligand binding, and produce autophosphorylation, induce the signal transduction pathway downstream of the cell, cause a series of cascade reactions, and thus affect the normal physiological functions of the body's cells. Eventually lead to the occurrence of tumors. High expression of EGFR has been found in many malignant tumors (such as breast cancer and non-small cell lung cancer) cells. EGFRvIII has not been detected in normal tissues so far, so it is regarded as malignant tumor-specific expression EGFR mutants provide new ideas for molecular targeted therapy of malignant tumors, and may therefore become an ideal target for molecular targeted therapy of malignant tumors. This product is a second-generation CAR lentiviral expression vector targeting hEGFRvIII, which can be used for in vivo and in vitro pharmacodynamic experiments.

Product name: Lenti-EF1a- hEGFRvIII -2nd-CAR

Promoter: EF1a [1]

Intracellular co-activation signal: 4- 1 BB /CD3Zata

Resistance gene: Amp


1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.